Opdivo/Yervoy Combo Fails in Renal Cancer Trial
The trial of the immunotherapy combination, although approved in other renal cell carcinoma indications, did not meet the endpoint of disease-free survival in patients with localized disease.
The phase 3 CheckMate-914 trial evaluating Opdivo (nivolumab) plus Yervoy (ipilimumab) as an adjuvant treatment for patients with localized renal cell carcinoma (RCC) did not meet the primary endpoint of disease-free survival, according to an announcement from Bristol-Myers Squibb. BMS was pursuing the combination to treat patients with localized renal cell carcinoma who have undergone full or partial removal of the kidney and who are at moderate or high risk of relapse.
The safety profile was consistent with previously reported studies of the Opdivo plus Yervoy combination in solid tumors.
Dana Walker, M.D.
“Even with notable progress in the treatment of metastatic renal cell carcinoma, there are still limited treatment options available for patients with localized disease,” Dana Walker, M.D., vice president, development program lead, genitourinary cancers, Bristol Myers Squibb, said in a press release. “We we are disappointed that the final analysis of CheckMate-914 Part A did not show this same benefit for the post-surgical treatment of patients with localized RCC. Nonetheless, we are dedicated to continuing research and advancing cancer care for all patients with RCC.”
Opdivo and Opdivo-based combinations have demonstrated clinical benefits across several RCC patient populations, including: the first-line treatment of patients with previously untreated, intermediate- and poor-risk renal cell carcinoma; with a tyrosine kinase inhibitor for the first-line treatment of patients with previously untreated advanced RCC; and Opdivo for the second-line treatment of patients with previously treated advanced or metastatic renal cell carcinoma.
The company is also investigating Opdivo and Opdivo plus Yervoy in combination with novel agents targeting alternative immunomodulatory molecules and pathways in renal cell carcinoma.
ICER Finds Insurers Struggled to Provide Fair Access for Obesity Drugs
December 19th 2024The Institute for Clinical and Economic Review assessed the formularies of 11 payers, covering 57 million people, to determine access for drugs that the organization had reviewed in 2022 for cost-effectiveness.
Read More
Using the 'Pathway' Approach to Shorten the Time Between Cancer Diagnosis and Treatment
November 16th 2022In this episode of Tuning In to the C-Suite, Briana Contreras, editor with Managed Healthcare Executive spoke with Dr. Yuri Fesko, oncologist and vice president of Medical Affairs at Quest Diagnostics. In the conversation, Dr. Fesko addressed the ongoing issue of long gaps of times between receiving a diagnosis for a type of cancer and finally getting the treatment for it. Dr. Fesko shared the benefits a number of sectors receive when treating patients sooner and the steps to get there.
Listen
